The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10917 malaria professionals are enjoying the free benefits of MalariaWorld today

uncomplicated

Progress and challenges of integrated drug efficacy surveillance for uncomplicated malaria in Thailand

June 16, 2021 - 12:34 -- Open Access
Author(s): 
Prayuth Sudathip, Aungkana Saejeng, Jui A. Shah, et al.
Reference: 
Malaria Journal 2021 20:261, 9 June 2021

Integrated drug efficacy surveillance (iDES) was formally introduced nationally across Thailand in fiscal year 2018 (FY2018), building on a history of drug efficacy monitoring and interventions. According to the National Malaria Elimination Strategy for Thailand 2017–2026, diagnosis is microscopically confirmed, treatment is prescribed, and patients are followed up four times to ensure cure.

Care-seeking behaviour and socio-economic burden associated with uncomplicated malaria in the Democratic Republic of Congo

June 16, 2021 - 12:32 -- Open Access
Author(s): 
Nadine Kalenda Kayiba, Doudou Malekita Yobi, Niko Speybroeck, et al.
Reference: 
Malaria Journal 2021 20:260, 9 June 2021

This study aimed to estimate the socio-economic costs of uncomplicated malaria and to explore health care-seeking behaviours that are likely to influence these costs in the Democratic Republic of Congo (DRC), a country ranked worldwide as the second most affected by malaria.

Genetic diversity and genetic relatedness in Plasmodium falciparum parasite population in individuals with uncomplicated malaria based on microsatellite typing in Eastern and Western regions of Uganda, 2019–2020

June 5, 2021 - 06:24 -- Open Access
Author(s): 
Agaba B. Bosco, Karen Anderson, Qin Cheng, et al.
Reference: 
Malaria Journal 2021 20:242, 31 May 2021

Genetic diversity and parasite relatedness are essential parameters for assessing impact of interventions and understanding transmission dynamics of malaria parasites, however data on its status in Plasmodium falciparum populations in Uganda is limited. Microsatellite markers and DNA sequencing were used to determine diversity and molecular characterization of P. falciparum parasite populations in Uganda.

Hematological indices and abnormalities among patients with uncomplicated falciparum malaria in Kosti city of the White Nile state, Sudan: a comparative study

June 1, 2021 - 15:47 -- Open Access
Author(s): 
Elkhalifa AME, Abdul-Ghani R, Tamomh AG, Eltaher NE, Ali NY, Ali MM, Bazie EA, KhirAlla A, DfaAlla FA, Alhasan OAM
Reference: 
BMC Infect Dis. 2021 May 31;21(1):507

Hematological abnormalities are common features in falciparum malaria but vary among different populations across countries. Therefore, we compared hematological indices and abnormalities between Plasmodium falciparum-infected patients and malaria-negative subjects in Kosti city of the White Nile State, Sudan.

Efficacy and safety of artemisinin-based combination therapies for the treatment of uncomplicated malaria in pediatrics: a systematic review and meta-analysis

April 14, 2021 - 16:50 -- Open Access
Author(s): 
Shibeshi W, Alemkere G, Mulu A, Engidawork E
Reference: 
BMC Infect Dis. 2021 Apr 7;21(1):326

Malaria is a major cause of morbidity and mortality in pediatrics in malaria endemic areas. Artemisinin-based combination therapies (ACTs) are the drugs of choice for malaria management particularly across malaria-endemic countries. This systematic review and meta-analysis was performed to assess efficacy and safety of ACTs for uncomplicated malaria in pediatric populations.

Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso

February 17, 2021 - 09:25 -- Open Access
Author(s): 
Siribie M, Tchouatieu AM, Sirima SB, et al.
Reference: 
BMJ Open. 2021 Feb 15;11(2):e040220

As demonstrated in mathematical models, the simultaneous deployment of multiple first-line therapies (MFT) for uncomplicated malaria, using artemisinin-based combination therapies (ACTs), may extend the useful therapeutic life of the current ACTs. This is possible by reducing drug pressure and slowing the spread of resistance without putting patients' life at risk. We hypothesised that a simultaneous deployment of three different ACTs is feasible, acceptable and can achieve high coverage rate if potential barriers are properly identified and addressed.

Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium falciparum malaria in Zanzibar

February 16, 2021 - 15:49 -- Open Access
Author(s): 
Leyre Pernaute-Lau, Ulrika Morris, Mwinyi Msellem, Andreas Mårtensson, Anders Björkman and Jose Pedro Gil
Reference: 
Malaria Journal 2021 20:90, 15 February 2021

The anti-malarial drug, amodiaquine, a commonly used, long-acting partner drug in artemisinin-based combination therapy, is metabolized to active desethyl-amodiaquine (DEAQ) by cytochrome P450 2C8 (CYP2C8). The CYP2C8 gene carries several polymorphisms including the more frequent minor alleles, CYP2C8*2 and CYP2C8*3. These minor alleles have been associated with decreased enzymatic activity, slowing the amodiaquine biotransformation towards DEAQ. This study aimed to assess the influence of these CYP2C8 polymorphisms on the efficacy and tolerability of artesunate–amodiaquine (AS–AQ) treatment for uncomplicated Plasmodium falciparum malaria in Zanzibar.

Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso

February 3, 2021 - 15:08 -- Open Access
Author(s): 
Yves Daniel Compaoré, Issaka Zongo, Jean Bosco Ouédraogo, et al.
Reference: 
Malaria Journal 2021 20:64, 29 January 2021

The use of pyronaridine-artesunate (PA) has been associated with scarce transaminitis in patients. This analysis aimed to evaluate the hepatic safety profile of repeated treatment with PA versus artemether–lumefantrine (AL) in patients with consecutive uncomplicated malaria episodes in Bobo-Dioulasso, Burkina Faso.

Severe orthostatic hypotension in otherwise uncomplicated Plasmodium vivax infection

January 13, 2021 - 08:33 -- Open Access
Author(s): 
Chaisith Sivakorn, Polrat Wilairatana, Srivicha Krudsood, Marcus J. Schultz, Tachpon Techarang, Khanittha Kheawsawaung and Arjen M. Dondorp
Reference: 
Malaria Journal 2021 20:28, 7 January 2021

Impaired autonomic control of postural homeostasis resulting in orthostatic hypotension has been described in falciparum malaria. However, severe orthostatic intolerance in Plasmodium vivax has been rarely reported.

Efficacy of Artemisinin-lumefantrine for treatment of uncomplicated malaria after more than a decade of its use in Kenya

January 5, 2021 - 14:47 -- Open Access
Author(s): 
Kishoyian G, Njagi ENM, Orinda GO, Kimani FT, Thiongo K, Matoke-Muhia D
Reference: 
Epidemiol Infect. 2021 Jan 5:1-24

The  resistance  of Plasmodium  falciparum to  antimalarial  drugs  remains  a  major impairment  in the treatment  and  eradication of malaria globally. Following the introduction of artemisinin-based combination therapy (ACT), there have been reports of delayed parasite clearance. In Kenya, artemether-lumefantrine (AL) is the recommended first-line treatment of uncomplicated malaria. This study sought  to  assess  the  efficacy  of  AL  after  a  decade  of use as the  preferred  method  of  managing  malarial  infections in Kenya. We assessed clinical and parasitological esponses of children under five years between May and November 2015 in Chulaimbo   sub-County,   Kisumu,   Kenya.

Pages

Subscribe to RSS - uncomplicated